Agree - also this is CNS - not cancer or infection disease where they can produce topline results based on Yes or No.
Also, if the obvious topline data is not as clear or statistical significant, then companies try to dig deeper to find good data from sub-groups. This takes time.
If the topline data is not announced in week of 13th then my guess will be that the data is not as good - surely not statatisticallybsignificant.
Exactly correct and since we are working in unplowed fields there is no template of, if this then...>. With luck we have patients who are responding well. Following conventional pass/fail protocol thinking finishing could be quickly done, but there is nothing conventional about the treatment being applied. Plus, no effective treatment has ever been developed for CNS diseases. There is no template, protocol or waypoint. In fact, some kind of interim result would be nice, but that is not how the system works. (for example) It would be great if they could say..."We are encouraged by the results, but we need to look deeper at the results", before we can call the results final.
But, that ain't gonna happen. We should be thinking this is not your conventional pass/fail mission. It is probably a pass (based on research and supporting trial controls). We will probably see more than a conventional trial close report. The PDD trial criteria are clear enough to do standard closure, but maybe it is more complicated/bigger than that.
Just a thought. But, this is an example of how breakthroughs first present themselves.
Market Data 
Markets 
AI
